Technologies that gather and store health-related data are generating real-world data (RWD) and real-world evidence (RWE) that are increasingly being applied in healthcare decision-making. As noted by the US Food and Drug Administration (FDA), RWD and RWE are assisting the agency in monitoring post-market safety and adverse events (AEs) and in making regulatory decisions. Deborah Komlos at Clarivate explains more about those regulatory decisions to clinical trials.